Anne Sullivan

Chief Business Officer @Prilenia

Boston, MA, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Sep 2022 — Present

Chief Business Officer @Prilenia

View department →

Waltham, MA, US

Prilenia Therapeutics B.V. is a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative and neurodevelopmental disorders. The company\'s lead asset, pridopidine, is an oral, highly selective Sigma-1 Receptor agonist that is currently being assessed in clinical studies as a potential treatment option for people living with Huntington\'s disease as well as ALS.

EDUCATION

N/A

The Tuck School of Business at Dartmouth

MBA, General Management

N/A

College of the Holy Cross

A.B., Economics/Accounting

SKILLS

Pharmaceutical IndustryFdaLife SciencesOncologyBiotechnologyMergers & AcquisitionsStart-UpsPharmaceutical SalesProduct DevelopmentTechnology TransferDrug DevelopmentLicensingCommercializationLifesciencesBusiness DevelopmentManaged CareClinical Development

ABOUT ANNE SULLIVAN

Senior biopharmaceutical executive with over 25 years industry experience working with both private, venture-backed biotech and large, multinational, public biopharmaceuticals. Significant functional expertise in corporate development, operations, marketing and sales with foundational experience in Finance/Accounting.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.